Quick Takeaways:
- Bora Biologics and Protect Animal Health have entered a long-term collaboration to develop and manufacture antibody-based veterinary products for US and global animal health markets.
- Protect plans to advance at least 3 programs, including 2 monoclonal antibody and 1 bispecific antibody program, with Bora supporting cell line development, process development, scale-up, and manufacturing.
- The partnership marks Bora Biologics’ first animal health collaboration, expanding its CHO-K1-based antibody development and manufacturing platform into veterinary medicine and strengthening Protect’s pipeline development capabilities.
Why It Matters?
Bora Biologics’ first animal‑health collaboration with Protect Animal Health gives Protect a U.S./Taiwan CDMO partner (CHO‑K1 cell line, process development, scale‑up, manufacturing) to advance at least three antibody programs (two mAbs, one bispecific) for US and global veterinary markets, accelerating pipeline de‑risking and time‑to‑market.
Source: Bora Biologics
